Current Status and Prospects of Vaccines based on DDS Technology.

Kawai, A.; Hirai, T.; Yoshioka, Y.

Kawai, A.; Hirai, T.; Yoshioka, Y..

Drug Delivery System ; 37(5):402-411, 2022.

Article in Japanese | EMBASE | ID: covidwho-2265819

ABSTRACT

ABSTRACT

The development of DDS technology has contributed critically to the unprecedentedly rapid requirement for vaccines against COVID-19. LNP-based mRNA vaccines represent a subset of DDS emerging DDS technology. Despite the groundbreaking nature of these vaccines, they are yet to be perfected and as such, new technologies are being developed to optimize these vaccines. This review will focus on exploring one of the modalities of recombinant protein vaccines and will introduce various findings on the enhancement of vaccine efficacy using antigen modification technologies, including VLPs and Fc-fusion proteins, and adjuvant improvements.Copyright © 2022, Japan Society of Drug Delivery System. All rights reserved.

Keywords

Adjuvant, DDS technology, Infection diseases, Recombinant protein vaccine, article, coronavirus disease 2019, drug delivery system, drug efficacy, human, infection, protein modification, review, technology, fusion protein, recombinant protein, recombinant vaccine, RNA vaccine, SARS-CoV-2 vaccine, vaccine

Fulltext

XML

Search on Google

Full text: Available Collection: Databases of international organizations Database: EMBASE Topics: Vaccines Language: Japanese Journal: Drug Delivery System Year: 2022 Document Type: Article

Similar

MEDLINE

LILACS

LIS

Fulltext

XML

Search on Google